Capricor Therapeutics, Inc. (CAPR)

$3.61

-0.12 (-3.22%)
Rating:
Recommendation:
Neutral
Symbol CAPR
Price $3.61
Beta 5.391
Volume Avg. 0.11M
Market Cap 87.810M
Shares () -
52 Week Range 2.56-5.85
1y Target Est -
DCF Unlevered CAPR DCF ->
DCF Levered CAPR LDCF ->
ROE -8.52% Neutral
ROA -4.14% Neutral
Operating Margin -
Debt / Equity 163.45% Buy
P/E -
P/B 3.56 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest CAPR news


Dr. Linda Marban
Healthcare
Biotechnology
NASDAQ Capital Market

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.